Molecular endotypes predict differential response to immunosuppressant therapy in non-IPF interstitial lung disease
In this multicenter observational cohort study, we identified and validated two distinct molecular endotypes of non-IPF ILD with divergent outcomes and response to immunosuppressant therapy. These endotypes could inform precision medicine strategies and clinical trial design in ILD.
Authors
- Janelle Vu Pugashetti (ORCID: https://orcid.org/0000-0002-8889-2757)
- Paul J. Wolters (ORCID: https://orcid.org/0000-0002-3108-6164)
- Christine Kim Garcia (ORCID: https://orcid.org/0000-0002-0771-1249)
- Ching‐Hsien Chen (ORCID: https://orcid.org/0000-0002-4211-9988)
- Samuel Konkol (ORCID: https://orcid.org/0000-0002-5229-8270)
- I Noth
- S. Pienkos
- A. R. Moore (ORCID: https://orcid.org/0000-0001-8040-2576)
- Manoj Maddali
- Mary E. Strek
- Chad Newton
- Ayodeji Adegunsoye
- Fernando J Martinez
- Rachel L Zemans
- Rishi Raj
- Angela L Linderholm
- John S Kim
- Justin M Oldham
- Jonathan H Chen
- Shwu-Fan Ma
Institutions
- University of Massachusetts Chan Medical School (US)
- University of California, San Francisco (US)
- University of Michigan (US)
- Columbia University Irving Medical Center (US)
- University of California System (US)
- University of Chicago (US)
- Stanford Health Care (US)
- Michigan Medicine (US)
- Stanford Medicine (US)
- Pulmonary and Critical Care Associates (US)
- University of Virginia (US)
- Columbia University (US)
- University of California, Davis (US)
- The University of Texas Southwestern Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- American Journal of Respiratory and Critical Care Medicine
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1093/ajrccm/aamag006
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00